Toyobo Co Ltd (JP:3101)
:3101
3101 Stock Chart & Stats
¥1275.00
-¥4.00(-0.42%)
At close: 4:00 PM EST
¥1275.00
-¥4.00(-0.42%)
Day’s Range― - ―
52-Week Range¥808.00 - ¥1,857.00
Previous CloseN/A
Volume273.20K
Average Volume (3M)305.73K
Market Cap
¥121.70B
Enterprise Value¥356.25B
Total Cash (Recent Filing)¥30.79B
Total Debt (Recent Filing)¥265.12B
Price to Earnings (P/E)13.3
Beta0.93
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.21%
Share Statistics
EPS (TTM)23.74
Shares Outstanding89,048,790
10 Day Avg. Volume223,990
30 Day Avg. Volume305,730
Financial Highlights & Ratios
PEG Ratio-2.24
Price to Book (P/B)0.43
Price to Sales (P/S)0.20
P/FCF Ratio-5.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)110.2
Revenue Forecast (FY)¥445.02B
Bulls Say, Bears Say
Bulls Say
Stable Revenue GrowthConsistent top-line growth indicates enduring demand for Toyobo's products across end markets. Steady revenues support long qualification cycles and customer relationships in specialty materials, enabling predictable production planning and investment in product development over months.
Strong Gross MarginA robust gross margin reflects manufacturing efficiency and pricing power in differentiated specialty polymers and films. This structural margin buffer helps absorb input-cost swings and underpins sustainable operating performance for the midterm, even if downstream SG&A or tax pressures persist.
Diverse Specialty Materials PortfolioBroad product mix spanning packaging, industrial applications, and life-science workflows reduces single-market concentration risk. Long customer qualification cycles and technical requirements for specialty materials create higher switching costs and recurring revenue potential over months to years.
Bears Say
Very Thin Net ProfitabilityExtremely low net margins limit the company's ability to convert operating strength into shareholder returns or retained earnings. Persistently thin profitability reduces resilience to cost inflation or demand shocks and constrains funding for strategic initiatives over the medium term.
Negative Free Cash FlowOngoing negative FCF from elevated capex undermines financial flexibility, increasing reliance on external financing to fund operations or growth. Over several months this can pressure liquidity, limit strategic optionality, and raise vulnerability to rising rates or funding stress.
Moderate Leverage And Weak ROEModerate leverage combined with very low ROE means borrowed capital is not generating attractive shareholder returns. This capital structure amplifies downside risk in cyclical downturns and constrains the firm's ability to improve returns without deleveraging or materially boosting profitability.
Toyobo Co News
3101 FAQ
What was Toyobo Co Ltd’s price range in the past 12 months?
Toyobo Co Ltd lowest stock price was ¥808.00 and its highest was ¥1857.00 in the past 12 months.
What is Toyobo Co Ltd’s market cap?
Toyobo Co Ltd’s market cap is ¥121.70B.
When is Toyobo Co Ltd’s upcoming earnings report date?
Toyobo Co Ltd’s upcoming earnings report date is Aug 06, 2026 which is in 125 days.
How were Toyobo Co Ltd’s earnings last quarter?
Toyobo Co Ltd released its earnings results on Feb 09, 2026. The company reported ¥23.74 earnings per share for the quarter, beating the consensus estimate of N/A by ¥23.74.
Is Toyobo Co Ltd overvalued?
According to Wall Street analysts Toyobo Co Ltd’s price is currently Overvalued.
Does Toyobo Co Ltd pay dividends?
Toyobo Co Ltd pays a Annually dividend of ¥40 which represents an annual dividend yield of 3.21%. See more information on Toyobo Co Ltd dividends here
What is Toyobo Co Ltd’s EPS estimate?
Toyobo Co Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Toyobo Co Ltd have?
Toyobo Co Ltd has 89,048,790 shares outstanding.
What happened to Toyobo Co Ltd’s price movement after its last earnings report?
Toyobo Co Ltd reported an EPS of ¥23.74 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 5.945%.
Which hedge fund is a major shareholder of Toyobo Co Ltd?
Currently, no hedge funds are holding shares in JP:3101
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Toyobo Co Ltd
Toyobo Co., Ltd. provides films and functional polymers, industrial materials, and healthcare and textile products worldwide. It offers industrial films, including PET films for liquid crystal display, optical, and other industrial use; and synthetic papers. The company also provides packaging films, such as PET, polyolefin, and nylon for food packaging, as well as heat-shrink PET films; functional polymers comprising engineering plastics, industrial adhesives, coatings, photo-sensitive printing plates, acrylate polymers, and electronic materials; rubber and coat processing; and pharmaceuticals intermediates. In addition, it offers functional fibers consisting of airbag fabrics; polyethylene and PBO fibers; functional filters for automobiles, indoor, and anti-pollution solvent adsorption materials and units; and fiber materials for automobile parts. Further, the company provides bio products, including enzymes for diagnostics, diagnostic systems, and reagents for research; artificial kidney hollow fibers; anti-clotting materials; seawater desalination modules; functional textiles for sports clothing, underwear, and uniforms; synthetic filaments; apparel under the Munsingwear brand; acrylic fibers under the Exlan brand; and acrylate fibers under the eks brand, as well as trades in textile products. Additionally, it operates as a contract manufacturer of injections. The company was founded in 1882 and is headquartered in Osaka, Japan.